FDA grants priority review to Genentech’s Enspryng for MOGAD

PUBT · 1d ago
FDA grants priority review to Genentech’s Enspryng for MOGAD
  • FDA granted Priority Review for a supplemental BLA for Genentech’s Enspryng to treat MOGAD.
  • Decision deadline set for Jan. 10, 2027; approval would make Enspryng the first disease-modifying therapy for MOGAD.
  • Filing backed by Phase III METEOROID results showing a 68% relapse-risk reduction versus placebo.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genentech Inc. published the original content used to generate this news brief on September 09, 2026, and is solely responsible for the information contained therein.